Orchard Therapeutics plc - ADR

+0.01 (+2.13%)
Earnings Announcements

Orchard Therapeutics Posts Qtrly Loss Per Share Of 35 Cents

Published: 05/12/2022 11:23 GMT
Orchard Therapeutics plc - ADR (ORTX) - Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress.
Otl-200 U.S. Bla Filing for Mld on Track for Late 2022 / Early 2023.
Cash and Investments of Approximately $200m Provide Runway Into 2024.
Qtrly Loss per Share $0.35.
Q1 Earnings per Share View $-0.26 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $3.5 Million
Adjusted EPS is expected to be -$0.26

Next Quarter Revenue Guidance is expected to be $3.04 Million
Next Quarter EPS Guidance is expected to be -$0.21

More details on our Analysts Page.